Women with metastatic triple-negative breast cancer had a more significant response to treatment with eribulin (Halaven) versus capecitabine (Xeloda) than women with other forms of breast cancer, with a median overall survival of 14.4 months with eribulin compared with 9.4 months with capecitabine. The results were part of a phase III multicenter study presented today at the San Antonio Breast Cancer Symposium.
The median overall survival for all patients assigned to eribulin was 15.9 months compared with 14.5 months for patients assigned to capecitabine. Median progression-free survival was 4.1 months for eribulin and 4.2 months for capecitabine.
Please consider a donation to Positives About Negative to keep this site going. This work is entirely supported by readers. Just click on the Donate button in the right of the page. Thank you!
Post a Comment